Trial
NCT05171075
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Anthos Therapeutics, Inc.
Collaborators
Novartis Pharmaceuticals
Condition
Venous Thromboembolism
Intervention
Abelacimab
Why stopped
Sponsor Decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-17